Project PEER: Understanding the Lung Cancer Patient ExperiEnce in the Real-World Setting

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

LUNGevity Foundation, a non-profit lung cancer organization, wants to learn about living with lung cancer from the point of view of people with lung cancer and their family and friends who provide care. To do this, we have an online study designed to better understand how treatments people living with lung cancer receive impact their quality of life. Participants will complete surveys once a month for 12 months. What does participation involve? 1. Emailing the study team to learn more and get access to the study website. 2. Once a month for 12 months you will receive a survey by email. 3. Complete these surveys on a smartphone, tablet, or computer at your convenience and receive an e-gift card for your time.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Adults with self-reported lung cancer diagnosis or caregiver of someone with a self-reported lung cancer diagnosis (patient has to be alive)

• Ability to read and answer questions in English

• Access and ability to use a computer or other internet-connected device

Locations
United States
Maryland
LUNGevity Foundation
RECRUITING
Bethesda
Contact Information
Primary
Tracey Grant, MS
ProjectPEER@lungevity.org
(312) 519-1322
Backup
Bellinda King-Kallimanis, PhD
ProjectPEER@lungevity.org
Time Frame
Start Date: 2020-08-15
Estimated Completion Date: 2025-12
Participants
Target number of participants: 1300
Treatments
Patients
Individuals who have been diagnosed with lung cancer. Individuals with all stages of lung cancer and individuals who have reached no evidence of disease (NED).
Caregivers
Family and friends who provide care for someone who has been diagnosed with lung cancer
Related Therapeutic Areas
Sponsors
Collaborators: Boehringer Ingelheim, Merck Sharp & Dohme LLC, Eli Lilly and Company, Janssen, LP, Jazz Pharmaceuticals, G1 Therapeutics, Inc., Novartis, Bristol-Myers Squibb, Amgen, Genentech, Inc., Blueprint Medicines Corporation, Takeda, AstraZeneca
Leads: LUNGevity Foundation

This content was sourced from clinicaltrials.gov